StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note released on Thursday. The brokerage issued a sell rating on the medical research company’s stock.
Organovo Price Performance
Shares of NASDAQ ONVO opened at $0.57 on Thursday. The firm has a fifty day moving average of $0.69 and a 200-day moving average of $0.90. Organovo has a 52-week low of $0.50 and a 52-week high of $2.05.
Organovo (NASDAQ:ONVO – Get Free Report) last issued its earnings results on Friday, May 31st. The medical research company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.13. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.08 million. As a group, analysts anticipate that Organovo will post -0.96 EPS for the current fiscal year.
Institutional Trading of Organovo
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
See Also
- Five stocks we like better than Organovo
- Most active stocks: Dollar volume vs share volume
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What is Put Option Volume?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.